Financial PerformanceThe company's newly announced FY3/29 revenue target of ¥230bn surpasses Jef and Visible Alpha estimates, suggesting strong confidence in future financial performance.
Research And DevelopmentThe company plans to invest a significant ¥190bn in R&D over five years, demonstrating a strong commitment to innovation and future growth.
Revenue ForecastThe company's forecast for FY3/29 revenue of ¥230bn assumes that Viltepso stays on the US market and gains approval in China and the EU, indicating potential for substantial market expansion.